MediFind
Condition

Lafora Disease

Latest Research

Latest Advance
Study
  • Condition: Nonepileptic Myoclonus in Angelman Syndrome
  • Journal: Brain & development
  • Treatment Used: Perampanel
  • Number of Patients: 4
  • Published —
This study tested the effectiveness of perampanel for nonepileptic myoclonus in patients with Angelman syndrome.
Latest Advance
Study
  • Condition: Congenital Generalized Lipodystrophy (CGL) with Progressive Myoclonic Epilepsy
  • Journal: Medicine
  • Treatment Used: Sodium Valproate, Baclofen, Aripiprazole, Benzhexol, Lamotrigine, and Nutrition Therapy
  • Number of Patients: 1
  • Published —
This case report discusses a child with congenital generalized lipodystrophy (CGL), a rare autosomal recessive hereditary disease, associated with metabolic complications and epilepsy, which is also rare.
Latest Advance
Study
  • Condition: Progressive Myoclonus Epilepsy
  • Journal: Epilepsy research
  • Treatment Used: Perampanel (PER)
  • Number of Patients: 49
  • Published —
This study assessed the effectiveness of perampanel (PER) on patients with progressive myoclonus epilepsy.
Latest Advance
Study
  • Condition: Refractory Cortical Myoclonus
  • Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • Treatment Used: Low-Dose Perampanel (PER)
  • Number of Patients: 18
  • Published —
This study clarified the effects of perampanel (PER) in the treatment of refractory cortical myoclonus (uncontrolled muscle jerks).
Latest Advance
Study
  • Condition: Lafora Disease
  • Journal: Orphanet journal of rare diseases
  • Treatment Used: Metformin
  • Number of Patients: 12
  • Published —
This study evaluated the effectiveness of metformin to treat patients with Lafora Disease (rare progressive epilepsy).
Latest Advance
Study
  • Condition: Unverricht-Lundborg Disease (ULD)
  • Journal: Seizure
  • Treatment Used: Anti-Epileptic Polytherapy
  • Number of Patients: 0
  • Published —
This study analyzed the clinical course, cognitive state, neuroimaging and neurophysiology results of patients with Unverricht-Lundborg disease (ULD) confirmed by molecular testing.